6Letters Launches "MOJO KING," an Apple Watch-Based iOS App for Non-Invasive Testosterone Monitoring

SEOUL, South Korea, Jan. 20, 2026 /PRNewswire/ -- Digital healthcare startup 6Letters today announced the official launch of MOJO KING, an iOS application that enables non-invasive monitoring of testosterone-related physiological patterns using Apple Watch data.

MOJO KING leverages heart rate variability (HRV)—a standard biometric signal collected by Apple Watch—to analyze changes associated with male hormonal balance. Without requiring blood tests or external sensors, the app allows users to track hormone-related trends seamlessly in everyday life.

The current version of MOJO KING analyzes individual biometric signals in relation to age-group baselines and 24-hour circadian rhythms. Based on this analysis, users are classified into intuitive categories: "Teto Guy" when values are above the age-adjusted average, or "Egen Guy" when below. Results are presented in a user-friendly visual format and can be easily shared via social media platforms such as Instagram.

With a paid subscription, users can remove in-app advertisements and enable automatic, continuous measurements, allowing them to observe personalized hormone-related changes over time. This supports a shift from one-time readings to longitudinal, trend-based hormone monitoring tailored to individual lifestyles.

MOJO KING is built on a foundation of multiple patents and peer-reviewed scientific research. To further enhance accuracy and personalization, 6Letters is currently training machine-learning models using large-scale medical datasets from the UK Biobank, CDC, Physionet etc. Insights derived from this work will power the next generation of the company's hormone analytics platform.

Notably, MOJO KING goes beyond conventional smartwatch fitness use cases that focus primarily on heart rate and respiration during aerobic exercise. The app introduces a differentiated approach by analyzing pre- and post-changes associated with moderate-to-high-intensity resistance training, offering new insights into hormone-related responses to strength-focused workouts.

Looking ahead, 6Letters plans to expand MOJO KING with additional modes, including hormone-dependent hair loss management and growth-phase optimization. The company is also preparing to launch MOJO QUEEN, a complementary digital health application focused on female hormone analytics.

In parallel, 6Letters is currently conducting a pre-seed funding round at an approximate company valuation of USD 5 million. The company expects to complete AI training based on a huge medical data and plans to apply for FDA 510(k) clearance in the first half of 2026, followed by entry into the U.S. Remote Patient Monitoring (RPM) reimbursement market.

MOJO KING is designed to help users understand and manage hormone-related physiological signals in everyday life, said a representative of 6Letters. By combining scientific evidence, large-scale medical data, and wearable technology, 6Letters aims to build a globally scalable digital hormone health platform.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

6Letters Launches "MOJO KING," an Apple Watch-Based iOS App for Non-Invasive Testosterone Monitoring

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"